US Nasdaq stock alert

USA

CLOSING UPDATE: Celgene hits 52-week high sixth time in one month 24 July 2017 17:53 EDT

NEWS BITES - NORTH AMERICA

This is an end of day Alert, produced after today's NASDAQ market close. It concludes the BSS News Bites intra-day Alert series (summaries below).

Celgene, NASDAQ's 2nd largest medical/biomedical company by market capitalisation, hit a 52-week high of $US138.93 today for the sixth time in the past one month and last traded at $US137.84. This brought its four-day rise to $US3.57 or 2.7%. Trading volume was 83% of average at the end of the day. Compared with the NASDAQ-100 Index which rose 9.5 points (or 0.2%) in the day, this represented a relative price change of -0.1%.

Technical indicators complementing today's significant uptrend:

+ The positive 3.01 MACD (Moving Average Convergence Divergence) indicator suggests a bullish signal.

+ In the last one month the stock has hit a new 52-week high five times and in the last three months seven times, pointing to a significant uptrend.

+ The price lifted 2.2% in the last week and 3.1% in the last month.

Fundamental measures by comparison with the sector average [in brackets] indicate:

Undervaluation:

+ Return on Equity 30.3% [6.2%]

+ Return on Assets 7.1% [2.9%]

Other Bullish Signals include:

+ Net profit margin has averaged 20.5% in the last 3 years. This is considered superior and suggests a high margin of safety.

+ As per the Du Pont analysis, Return on Equity is high at 30.3%. Also, this has improved from 27.1% last year.

Note

The stock has outperformed 75% of the NASDAQ market over the past 6 months.

Bearish Signals:

Tobin's Q Ratio is 3.8. Compared with the rest of the market the stock is overvalued and ranks in the bottom quartile of stocks by value of Q Ratio.

Overbought/Bearish:

The 0.8% discount to 12-month high of $US138.93 against the 42.2% premium to 12-month low of $US96.93 suggests the climb might be peaking.

Fundamental measures by comparison with the sector average [in brackets] indicate:

Overvaluation:

Price/Sales of 9.2 [4.9]

Return on Capital Employed 11.4% [15.5%]

TODAY'S ALERTS

Afternoon Alert: Celgene in 4th consecutive rise, nears a 35-month high

24 July 2017 13:30 EDT

Celgene Corporation (NASDAQ:CELG) extended its gains Monday, rising an additional 54.21c (or 0.4%) to trade at $US138.28. The stock increased 0.97% on Thursday and 1.05% on Friday bringing its 4-day rise to 3.0%. It is now approaching its twenty-five-month high of $US138.93.

Morning Alert: Celgene in 4th consecutive rise, nears a 35-month high

24 July 2017 11:01 EDT

Celgene Corporation (NASDAQ:CELG) extended its gains Monday, rising an additional 50.0c (or 0.4%) to trade at $US138.24. The stock increased 0.97% on Thursday and 1.05% on Friday bringing its 4-day rise to 3.0%. It is now approaching its twenty-five-month high of $US138.30.

RECENT ALERTS

CLOSING UPDATE: Celgene keeps rising: up 2.6% in 3 days

21 July 2017 17:53 EDT

Celgene, NASDAQ's 2nd largest medical/biomedical company by market capitalisation, extended its gains on Friday, rising an additional $US1.43 (or 1.0%) to trade at $US137.74. Trading volume was 68% of average at the end of the day.

Afternoon Alert: Celgene keeps rising: up 2.7% in 3 days

21 July 2017 13:29 EDT

Celgene Corporation (NASDAQ:CELG) extended its gains on Friday, rising an additional $US1.60 (or 1.2%) to trade at $US137.91. Trading volume was 1.3 times average so far today.

Celgene Corporation (O:CELG)

ISIN: US1510201049

PermID: 4295905897

CIK: 816284

CUSIP: 151020104

Source: www.BuySellSignals.com